
LRMR Stock Forecast & Price Target
LRMR Analyst Ratings
Bulls say
Larimar Therapeutics Inc. has demonstrated promising advancements with its lead product candidate, CTI-1601, evidenced by a significant increase in median frataxin (FXN) expression from 2.7 pg/μg at baseline to 13.44 pg/μg at the six-month mark, indicating the product's potential efficacy in treating Friedreich's ataxia. Additionally, the company reported a median improvement of -2.20 points on the modified Friedreich's Ataxia Rating Scale (mFARS), contrasting with a decline of +1.00 points observed in the FACOMS natural history population over the same period, which underscores the therapeutic benefits of CTI-1601. These compelling clinical results position Larimar Therapeutics favorably within the biotechnology sector, signifying its capacity to address unmet medical needs in the rare disease space.
Bears say
Larimar Therapeutics's financial outlook has been negatively impacted by a significant decrease in its FY29 revenue estimate, lowering from $659 million to $407 million, which raises concerns regarding the company's growth potential in the Friedreich's ataxia market. Additionally, the median change in the modified Friedreich Ataxia Rating Scale (mFARS) demonstrates a concerning decline of -2.20 points over one year for CTI-1601, indicating less favorable outcomes compared to a decline of +1.00 point in the FACOMS natural history population. This disparity in clinical outcomes further compounds the challenges faced by the company in achieving its market share goals, casting doubt on the viability of its lead product candidate.
This aggregate rating is based on analysts' research of Larimar Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LRMR Analyst Forecast & Price Prediction
Start investing in LRMR
Order type
Buy in
Order amount
Est. shares
0 shares